Biliary glycoprotein (Bgp) is a member of the immunoglobulin superfamily and the carcinoembryonic antigen family. Previous studies have shown that Bgp functions as an intercellular adhesion molecule and a canalicular bile salt transporter. Moreover, we and others demonstrated that Bgp can inhibit colonic and prostatic tumor cell growth in vivo, through a mechanism which depends on sequences present in its cytoplasmic domain. In this study, we have examined the possibility that the cytoplasmic domain of Bgp can interact with signal transduction molecules. We showed that tyrosine phosphorylated Bgp, expressed in mouse colon carcinoma CT51 cells, could reversibly associate with protein tyrosine phosphatase SHP-1. Mutation of either of two tyrosine residues present in the cytoplasmic domain of Bgp abrogated SHP-1 binding, suggesting that this association was mediated by both tyrosine residues. Similarly, we noted that either of the two SH2 domains of SHP-1 could bind tyrosine phosphorylated Bgp in vitro. It is therefore conceivable that some of the functions of Bgp are mediated through its ability to induce intracellular protein tyrosine dephosphorylation.
Introduction
Biliary glycoprotein (Bgp) is a cell-surface immunoglobulin-like protein and a member of the carcinoembryonic antigen (CEA) family (Thompson et al., 1991) . Bgp is well conserved throughout evolution. The human, mouse and rat Bgp proteins exhibit very similar extracellular domains (Barnett et al., 1989; Lin and Guidotti, 1989; O È brink, 1991; McCuaig et al., 1992) . However, their most conserved feature is in their cytoplasmic domains, which exhibit 77 ± 92% similarity at the amino acid level. Bgp proteins possess cytoplasmic domains of either 10 or 71 (73 in mouse) amino acids which are produced by alternative splicing of a conserved 53 bp exon (Barnett et al., 1989; NeÂ dellec et al., 1995) . They are mainly expressed in epithelial cells of the gastro-intestinal tract, endothelial cells and hematopoietic cells, particularly B cells, neutrophils and macrophages (Hinoda et al., 1988; Barnett et al., 1989; O È brink, 1991; Coutelier et al., 1994; NeÂ dellec et al., 1995) .
Bgp is multifunctional. First, it behaves as an intercellular adhesion molecule as demonstrated by in vitro aggregation assays (Ocklind and O È brink, 1982; Rojas et al., 1990; McCuaig et al., 1992) . This function is postulated to be important for maintenance of tissue architecture during embryonic development (Ocklind and O È brink, 1982; Daniels et al., 1996) . Second, Bgp can also promote extrusion of bile salts from cells (Sippel et al., 1993) . Third, Bgp has been implicated in mediating the internalization of the insulin receptor in the rat, a process which may relate to the ability of insulin treatment to induce tyrosine phosphorylation of Bgp (Margolis et al., 1988; Najjar et al., 1995; Formisano et al., 1995) . Fourth, we and others showed that Bgp expression is down-regulated in intestinal, liver and prostate tumors when compared to their normal counterparts (Hixson et al., 1985; Rosenberg et al., 1993; Neumaier et al., 1993; Hsieh et al., 1994) . Furthermore, enforced expression of Bgp into mouse colon carcinoma cells (CT51) or prostate carcinoma cells led to inhibition of tumor cell growth in mice (Kunath et al., 1995; Hsieh et al., 1995) . And ®nally, mouse Bgp functions as a receptor for Mouse Hepatitis Virus (MHV) (Dveksler et al., 1991; NeÂ dellec et al., 1994) .
It is interesting that some of the functions of Bgp, such as participation in bile acid transport (Sippel et al., 1994) , regulation of insulin receptor internalization and inhibition of tumor cell growth in vivo (Kunath et al., 1995; Hsieh et al., 1995) are dependent on the longer cytoplasmic domain of Bgp. In contrast, other functions like adhesion (McCuaig et al., 1992) and binding and internalization of MHV (Dveksler et al., 1991) do not necessitate this sequence. While the role of the cytoplasmic domain of Bgp is not precisely known, the longer cytoplasmic domain contains two Tyr residues within a sequence motif related to that of Immunoreceptor Tyrosine-based Activation Motifs (ITAMs) (Figure 1a and b) . Both tyrosine residues in this motif are usually phosphorylated and separated by 6 ± 8 amino acids (Reth, 1989; Weiss and Littman, 1994) . The similarity of Bgp to this sequence is imperfect though, as the spacing between the two Tyr in Bgp (26 aa) is greater than that found in classical ITAMs. Moreover, in contrast to ITAMs, only one tyrosine of Bgp (Tyr 488 ) was convincingly shown to undergo phosphorylation in cells treated with insulin or with the protein tyrosine phosphatase inhibitor vanadate . Recently, several hematopoietic cell surface receptors, such as the erythropoietin receptor (Klinmuller et al., 1995) , the IL-3 receptor, Kit (Yi et al., 1993a,b) , FcgRIIB1, the natural killer receptor p58 and B cell antigen receptor (D'Ambrosio et al., 1995; Pani et al., 1995; Burshtyn et al., 1996) have been shown to contain a so-called Immunoreceptor Tyrosine-based Inhibition Motif (ITIM) (D'Ambrosio et al., 1995; Burshtyn et al., 1996) . This motif is shorter than that of the ITAMs (Figure 1c ) and encompasses a single phosphorylated tyrosine residue followed at position +2 relative to the tyrosine by an obligate leucine. In this respect, the ®rst half of the Bgp motif centered around Tyr 488 coincides perfectly with the ITIM motif (Figure 1c) .
To address the function provided by the cytoplasmic domain of Bgp, we have examined its ability to associate with tyrosine phosphorylated cellular proteins. In cells treated with the protein tyrosine phosphatase inhibitor pervanadate, we observed that Bgp was speci®cally complexed with a 66 kDa-tyrosine phosphorylated protein. Immunoblot analyses showed that this protein was SHP-1 (also known as PTP1C, HCP, SH-PTP1, SHP), a cytosolic protein tyrosine phosphatase containing two SH2 domains in its amino-terminal region (Matthews et al., 1992; Plutzky et al., 1992; Adachi et al., 1996) . Structure-function analyses showed that this association required tyrosines 488 and 515 of Bgp. Moreover, in vitro binding studies indicated that either of the two SH2 domains of SHP-1 could bind tyrosine phosphorylated Bgp. Together, these results suggested that part of the role of the Bgp cytoplasmic domain may be to mediate recruitment of SHP-1 and regulate intracellular protein tyrosine phosphorylation.
Results

Tyrosine phosphorylation of Bgp in pervanadate-treated colonic epithelial cells
To characterize the role of the cytoplasmic domain of Bgp in epithelial cells, we ®rst focused on the potential functions of its tyrosine phosphorylation. Since the mechanisms regulating tyrosine phosphorylation of Bgp have not been clearly de®ned, we chose to arti®cially induce Tyr phosphorylation by treatment with pervanadate, a potent inhibitor of cellular protein tyrosine phosphatases (O'Shea et al., 1992) . This choice was based on the observation of others, which showed that vanadate, a less active protein tyrosine phosphatase inhibitor was ecient at provoking phosphorylation of Bgp at Tyr 488 .
Derivatives of CT51 colon carcinoma cells expressing various forms of Bgp proteins were incubated with pervanadate, lysed in non-ionic detergent-containing buers and Bgp was immunoprecipitated from cell lysates using anti-Bgp polyclonal antibodies. Tyrosine phosphorylated proteins were detected by immunoblotting with anti-phosphotyrosine antibodies (Figure 2a ), while the abundance of Bgp was monitored by immunoblotting with anti-Bgp antibodies ( Figure 2b ). As parental CT51 cells do not express Bgp Figure 2b , 1996) . The Y2, Y5 and Y6 residues represent the phosphotyrosines described in CD22 (Doody et al., 1995) was tyrosine-phosphorylated with a lower eciency than wild-type Bgp (Figure 2a, lanes 10 and 11) . These results suggested that Tyr 488 was the major site of tyrosine phosphorylation in Bgp. Finally, mutation of both tyrosines (Y488,515F) completely abolished Bgp Tyr phosphorylation (Figure 2a, lanes 14 and 15) . In combination, these results indicated that Tyr 488 was the major site of tyrosine phosphorylation in pervanadate-treated cells. However, they also suggested that Tyr 515 was either a minor phosphorylation site, or was required for maximal phosphorylation of Tyr 488 .
Association of Bgp with tyrosine phosphorylated SHP-1 in pervanadate-treated cells
To investigate whether Tyr phosphorylated Bgp could bind to other cellular proteins, Bgp was immunoprecipitated with anti-Bgp antibodies and Bgp-associated proteins were detected by anti-phosphotyrosine immunoblotting. In pervanadate-treated cells, immunoprecipitation of Bgp with either polyclonal or monoclonal antibodies consistently led to the detection of another Tyr phosphorylated-protein of approximately 66 kDa ( Figure 3, lane 2) . A second phosphorylated protein of approximately 100 kDa was also detected. The identity of this protein remains presently unknown.
Two cytosolic protein tyrosine phosphatases, SHP-1 and SHP-2, each carrying two N-terminal SH2 domains are known to associate with tyrosine phosphorylated receptors (Matthews et al., 1992 (Matthews et al., 1992; Plutzky et al., 1992) . In contrast, SHP-2, a 70 kDa polypeptide, is ubiquitously expressed (Vogel et al., 1993 To demonstrate that the 66 and 120 kDa polypeptides represented SHP-1 and Bgp respectively, Bgp was ®rst immunoprecipitated with a Bgp-speci®c monoclonal antibody, and Bgp and SHP-1 were detected by immunoblotting with the appropriate antibodies (Figure 4a, top and bottom) . While SHP-1 was not present in the Bgp immune complexes from untreated cells (Figure 4a, lane 1) , it was detectable in Bgp immunoprecipitates from pervanadate-treated cells (Figure 4a, lane 2) . These results were also con®rmed by the reverse experiment. When SHP-1 was immunoprecipitated from pervanadate-treated cells, Bgp was detected by anti-Bgp immunoblotting (Figure 4b, lanes 7 and 8) . These results suggested that Tyr phosphorylated Bgp protein was associated with SHP-1.
To determine whether tyrosine phosphorylation of Bgp was needed for association with SHP-1, the ability of the various Y?F mutants to bind SHP-1 in pervanadate-stimulated cells was examined. Mutations of either Tyr 
Binding of SH2 domains of SHP-1 to Tyr phosphorylated Bgp
To de®ne which domains of the SHP-1 phosphatase were contacting Bgp, in vitro binding assays were performed with bacterially-produced glutathione-Stransferase (GST) fusion proteins encompassing various domains of SHP-1. Lysates from CT51 Bgpexpressing cells treated or not with pervanadate were adsorbed onto GST fusion proteins bound to agarose glutathione beads. After several washes, binding proteins were eluted, resolved by electrophoresis and detected by immunoblotting with anti-Bgp antibodies. No Tyr phosphorylated protein bound to GST alone (Figure 5a, lanes 1 and 2) . However, a 120 kDa polypeptide consistent with Bgp bound to a GST (7) with pervanadate for 10 min at 378C were incubated for 3 h at 48C with various GST fusion proteins, comprising either none (GST) one (GST-SH2-N or SH2-C) or both (GST-SH2X2) SHP-1 SH2 domains, or the full-length SHP-1 phosphatase (GST-SHP-1), which had been immobilized on glutathione-Sepharose beads. The beads were washed, and the bound proteins resolved by electrophoresis and immunoblotted with anti-Bgp antibodies (Ab 231). The positions of the molecular weight markers (in kilodaltons) as well as the position of Bgp, SHP-1 and Ig are indicated. (b) The same experiment was repeated with the cell lysate proteins prepared from the CT51 cells expressing the Y515F mutant Bgp (cl 17) (lanes 1 ± 6) or cells expressing the wild-type BgpL (cl 12) (lanes 7 and 8). (c) Total cell lysate proteins from the clones mentioned above were subjected to immunoprecipitations with antibodies to Bgp (Ab 231). The immune complexes were collected on protein A Sepharose beads, the proteins were denatured, resolved by SDS ± PAGE electrophoresis and transferred to membranes which were immunoblotted with anti-phosphotyrosine antibodies pY20 and pY72 fusion protein containing full-length SHP-1 (Figure 5a , lanes 9 and 10) or bearing one or both SHP-1 SH2 domains (Figure 5a, lanes 3 ± 8) . This binding occurred only when Bgp was Tyr phosphorylated (Figure 5c , lane 2). This result suggested that either SHP-1 SH2 domain could associate with Bgp Tyr residues in vitro. In order to examine whether the presence of Tyr 488 was sucient for binding to the SHP-1 SH2 domains, the ability of GST-SHP-1 fusion proteins to associate with tyrosine phosphorylated Y515F Bgp was tested. We found that Y515F Bgp did not bind to either SHP-1 SH2 domain or to full-length SHP-1 (Figure 5b , lanes 2 ± 6), whereas the wild-type BgpL bound to the fulllength SHP-1 (Figure 5b, lanes 7 and 8) . Similar results were obtained with the Y488F Bgp mutant (data not shown). The results from the in vitro experiments concurred with those obtained in vivo (Figure 4) , suggesting that Bgp-SHP-1, association required contact with more than Tyr 488 .
Discussion
In this study, we provided evidence that Tyr phosphorylated Bgp interacted with SHP-1, a protein tyrosine phosphatase expressed in cells of hemopoietic and epithelial lineages. This was demonstrated using combinations of immunoprecipitation and immunoblotting of Bgp and SHP-1 proteins expressed in CT51 colon epithelial cells. This interaction was seemingly mediated by the tyrosine phosphorylated form of Bgp and the SH2 sequences of SHP-1.
Mutational analyses of Tyr residues in the cytoplasmic domain of Bgp provided evidence that Tyr 488 of Bgp was the only site of Bgp tyrosine phosphorylated in pervanadate-treated conditions. This result was in agreement with previous reports that utilized phosphopeptide mapping to reveal Tyr 488 as the only tyrosine phosphorylated in insulin-treated cells (Sippel et al., 1994; Najjar et al., 1995) . Therefore, the Bgp-SHP-1 complex was presumably mediated by Tyr 488 of Bgp. However, it should be noted that mutation of Tyr 515 also abrogated the interaction between Bgp and SHP-1, suggesting that Bgp-SHP-1 binding may actually be mediated by both tyrosine residues. It remains possible that Tyr 515 may also be transiently phosphorylated in vivo. Our results also indicated that one or the other SH2 domains of SHP-1 bound to tyrosine phosphorylated Bgp. However, the anity of each SH2 domain for binding to phosphorylated tyrosine of Bgp may be somewhat dierent and will need to be evaluated.
Several models can be envisaged for the Bgp-SHP-1 association. Phosphorylated Tyr 488 may be the sole binding site for one or the other SHP-1 SH2 domains. In this regard, our results were consistent with a recent report from Pei et al. (1996) demonstrating that both SHP-1 SH2 domains can associate independently with the same Tyr residue of FcgRIIB1, albeit with a ®vefold dierence in the K D of their binding. The authors of this report proposed a role for the SHP-1 N-SH2 domain in regulation of SHP-1, enzymatic activity as well as recruitment to the receptor phosphotyrosine residue, while the C-SH2 domain would primarily be involved in recruitment (Pei et al., 1996) . On the other hand, it is possible that in vivo, (Margolis et al., 1988; Najjar et al., 1995) and phosphorylation of this residue as well as Ser 503 phosphorylation correlate with ecient bile salt extrusion and insulin receptor endocytosis (Sippel et al., 1994; Formisano et al., 1995) . Similarly, Bgp was shown to be Tyr phosphorylated by pp60 c-src in human colonic carcinoma cells (BruÈ mmer et al., 1995) and by p53/56 lyn in human neutrophils (Skubitz et al., 1995) .
Our study provides the ®rst report of association of SHP-1 with a cell surface protein in epithelial cells. Other cell surface receptors bind to SHP-1 in hemopoietic cells (Yi et al., 1993a; Klinmuller et al., 1995; Pani et al., 1995; Burshtyn et al., 1996) . Binding of SHP-1 to the ITIM sequence in all these cell surface proteins terminates signalling with profound eects on cellular proliferation. However, we found no evidence that SHP-1 association altered the inhibitory eect of Bgp in CT51 cells (Turbide et al., unpublished) , using Tyr phosphorylation-defective Bgp mutants, incapable of binding SHP-1.
Bgp has been implicated in many cellular events such as intercellular adhesion, bile salt transport, insulin receptor internalization and inhibition of tumor cell growth (Ocklind and O È brink, 1982; Rojas et al., 1990; McCuaig et al., 1992; Sippel et al., 1993; Kunath et al., 1995; Formisano et al., 1995; Hsieh et al., 1995) . All of the above functions, except adhesion (Rojas et al., 1990; McCuaig et al., 1992) depend on the presence of the longer cytoplasmic domain of Bgp . Bgp may also act as a cell surface receptor and while Bgp ligands have not yet been identi®ed, it is conceivable that engagement of Bgp by its ligand(s) results in Bgp tyrosine phosphorylation. Alternatively, rat Bgp has been shown to be Tyr phosphorylated by the insulin receptor following insulin treatment (Margolis et al., 1988; Najjar et al., 1995) . Since SHP-1 associates with the insulin receptor via its carboxy-terminal end (Uchida et al., 1994) , it is tempting to speculate that it could mediate interactions between the insulin receptor and Bgp. Association of SHP-1 with Tyr phosphorylated Bgp may be required to facilitate the recruitment of the tyrosine phosphatase to the cell membrane, possibly within macromolecular complexes (such as that found with the insulin receptor). This may then possibly lead to termination of insulin receptor endocytosis or other events by dephosphorylation.
Further functional studies will be needed to investigate the respective functions of Bgp and SHP-1 in epithelial cells. These can be pursued in the SHP-1-de®cient motheaten mouse (Tsui et al., 1993) and in a bgp1 7/7 mouse.
Materials and methods
CAM, cell-cell adhesion molecule; GST, glutathione-Stransferase; PKC, protein kinase C; FACS,¯uorescence-activated cell sorting; ITAM, Immunoreceptor Tyrosinebased Activation Motif; ITIM, Immunoreceptor Tyrosinebased Inhibition Motif.
